| ||||||
|
Learn
    
|
Learn |
|||||
Novel TherapiesAfter learning of their diagnosis, many patients try a variety of alternative methods. Since stress is never good for the immune system, it can be said that stress-reduction is, in general, a good thing. It doesn't really lead to lengthy remissions, however, unless there was overwhelming stress in the beginning, and even here, it is unrealistic to expect that interventions like chiropractic manipulations or even energy work (massage, acupuncture, etc.) will do much for most patients on any kind of long term basis with respect to HPV/RRP. Alternative approaches also include taking a variety of vitamins, herbs (e.g., echinacea) or homeopathic remedies (e.g. thuja). None of these can be said to offer significant benefit with respect to RRP, however. The serum (blood borne) immune system isn't what's lacking in the RRP patient. It's the local immune system, and here naturopathic and homeopathic remedies seem pretty ineffective. Exercise is necessary for health, but this too isn't a viable approach in dealing with RRP. It is uncertain whether the use of Gardasil and artemisinin can in fact be properly called "alternative," but this particular approach has appeared to actually induce long term remission in one very refractory patient (viz., the executive director of RRP ISA). It also seems to have greatly helped a young man whose father (Keith S.) recently posted on our previous message board after following our guidelines. It in other words, it appeared to help 100% of the two patients who bothered to report in. Our voices are now reportedly "excellent. This writer has just been diagnosed (4/17/08) after two years of remission with a small papilloma. His voice is still excellent. He will be monitoring the situation. For more on this topic, please see the articles below and the material in the sub-menus.
Artemisinin Dr. Richard Schlegel, at Georgetown University, has been using artemisinin and artemisinin-like compounds. for some years. He reported on this at the 2005 RRP Focus Session meeting sponsored by RRP ISA. On the subject of efficacy, another report showed that "the deoxoartemisinin trimer was found to have greater antitumor effect on tumor cells than other commonly used chemotherapeutic drugs, such as 5-FU, cisplatin, and paclitaxel. Furthermore, the ability of artemisinin and its derivatives to induce apoptosis highlights their potential as chemotherapeutic agents, for many anticancer drugs achieve their antitumor effects by inducing apoptosis in tumor cells. © 2006 Wiley Periodicals, Inc. Head Neck, 2007." Here is more introductory data on artemisinin: Artemsinin abstracts and URLS Cancer smart bomb. Very informative: Calcium and survivin are involved in the induction of apoptosis by dihydroartemisinin in human lung cancer SPC-A-1 cells. www.ncbi.nlm.nih.gov/entrez/query.fcgi
Artesunate in the treatment of metastatic uveal melanoma--first experiences. From the University of Washington - this appears to be pretty current as it lists publications related to effects of aArtemisinin and its analogs on Cancer many of which are dated 2007. Dr. Richard Schlegel is highly respected HPV researcher who is currently working under a Bill and Melinda Gates Foundation grant. In the 2007 RRP Focus Session presentation, he explained his research in using L1 VLP vaccine, similar to Gardasil. Dr. Schlegel's presentation was quite detailed, showing that a vaccine like Gardasil was powerfully therapeutic. He noted that immunoglobulins are irrelevant to therapy. He strongly supported RRP ISA's research proposal to study Gardasil and artemisinin in tandem (this is NOT interlesional Gardasil to which we refer--this is not a "Dr. Strangelove/MMR redux protocol"--but use of Gardasil in a standard immunization protocol). In private discussion with RRP ISA, Dr. Ian Frazer, the noted Australian immunologist who can claim many of the patent rights on Gardasil, also has asserted that VLPs like Gardasil may indeed exert a therapeutic effect on RRP. Indeed, he indicated his RRP therapeutic vaccine currently being tested (2007) was very much like Gardasil, but without the alum adjuvant. It should be noted that Merck's conclusion that Gardasil doesn't work therapeutically is based ONLY on cervical and genital data. We believe that generalizing zero therapeutic efficacy from cervical data is simply bad science. On the RRP ISA message board (March 28, 2008), Dr. Bettie Steinberg--a molecular biologist who is an highly respected expert on RRP and HPV--made the following observation. Dr. Steinberg wrote:
RRP ISA has long said that there is good reason to conclude that the respiratory tract behaves differently from the genital tract (see argument referring to RRP epidemiology amongst AIDS patients to which Michael Green referred in RRP ISA's 2007 RRP Focus Session). Merck's own medical staff have privately admitted they do not know what Gardasil (or other VLPs) will do or not do in the respiratory tract. They haven't ever tested for efficacy outside the genital region. The following excerpt from an email sent to RRP ISA adds further credibility to our speculations. Dr. Richard Schlegel has given us permission to publish it here., From: Richard Schlegel _______________________________
|
||||||
